Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garth Powis

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|July 1, 2010
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerDavid L Schwartz, James A Bankson, Robert Lemos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in miceJörg J Jacoby, Baruch Erez, Maria V Korshunova, et al.
Cancer Research|October 6, 2019
Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor GrowthMarco Maruggi, Fabiana Izidro Layng, Robert Lemos, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in miceMei Yee Koh, Mihai Gagea, Timothy Sargis, et al.
BMC Cancer|March 10, 2016
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systemsHae Ryung Chang, Hee Seo Park, Young Zoo Ahn, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Oncotarget|May 12, 2016
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer modelsMichael S Lee, Timothy L Helms, Ningping Feng, et al.
Cancer Research|June 4, 2009
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKTSylvestor A Moses, M Ahad Ali, Song Zuohe, et al.
Molecular Cancer Therapeutics|October 26, 2014
The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progressionJeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 2, 2013
FXR silencing in human colon cancer by DNA methylation and KRAS signalingAnn M Bailey, Le Zhan, Dipen Maru, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|July 1, 2010
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerDavid L Schwartz, James A Bankson, Robert Lemos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in miceJörg J Jacoby, Baruch Erez, Maria V Korshunova, et al.
Cancer Research|October 6, 2019
Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor GrowthMarco Maruggi, Fabiana Izidro Layng, Robert Lemos, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in miceMei Yee Koh, Mihai Gagea, Timothy Sargis, et al.
BMC Cancer|March 10, 2016
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systemsHae Ryung Chang, Hee Seo Park, Young Zoo Ahn, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Oncotarget|May 12, 2016
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer modelsMichael S Lee, Timothy L Helms, Ningping Feng, et al.
Cancer Research|June 4, 2009
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKTSylvestor A Moses, M Ahad Ali, Song Zuohe, et al.
Molecular Cancer Therapeutics|October 26, 2014
The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progressionJeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 2, 2013
FXR silencing in human colon cancer by DNA methylation and KRAS signalingAnn M Bailey, Le Zhan, Dipen Maru, et al.
Pageof 10